zintick

Orthopediatrics KIDS

Orthopediatrics Corp · Nasdaq · Surgical & Medical Instruments & Apparatus

$30.80+29.30%close on Oct. 28, 2026 · volume 1.8M · Yahoo Finance

Price, last 47 sessions

$22.50$25.00$27.50$30.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $30.80 · low $21.56 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Sept. 10, 2026Squadron Capital LLC
with Squadron Capital Holdings LLC
10% owner
Sold302,369$21.01$6.35 million
Sept. 10, 2026Jennifer N. Pritzker
10% owner · indirect
Sold302,369$21.01$6.35 million
Sept. 10, 2026David R. Pelizzon
director, 10% owner · indirect
Sold302,369$21.01$6.35 million
Sept. 2, 2026Squadron Capital LLC
with Squadron Capital Holdings LLC
10% owner
Sold22,500$23.35$525,375
Sept. 2, 2026Jennifer N. Pritzker
10% owner · indirect
Sold22,500$23.35$525,375
Sept. 2, 2026David R. Pelizzon
director, 10% owner · indirect
Sold22,500$23.35$525,375
Sept. 1, 2026Squadron Capital LLC
with Squadron Capital Holdings LLC
10% owner
Sold10,131$23.10$234,026
Sept. 1, 2026Jennifer N. Pritzker
10% owner · indirect
Sold10,131$23.10$234,026
Sept. 1, 2026David R. Pelizzon
director, 10% owner · indirect
Sold10,131$23.10$234,026
Aug. 28, 2026Squadron Capital LLC
with Squadron Capital Holdings LLC
10% owner
Sold326,700$23.04$7.53 million
Aug. 28, 2026Jennifer N. Pritzker
10% owner · indirect
Sold326,700$23.04$7.53 million
Aug. 28, 2026David R. Pelizzon
director, 10% owner · indirect
Sold326,700$23.04$7.53 million

Latest 12 of 21. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 20 →
  • 10-QOct. 28, 2026, 2:09 p.m. ETView on SEC.gov
  • 8-KOct. 27, 2026, 4:15 p.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedOrthoPediatrics Investor Presentation (Ex. 99.1) Reiterates FY2026 Revenue Guidance of $270.0 to $273.0 Million and Shows 3Q 2026 Revenue Up 19% to $72.7 Million

  • 8-KOct. 27, 2026, 4:07 p.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedOrthoPediatrics Q3 2026 Revenue Rises 19% to Record $72.7 Million, Beats $68.5 Million Consensus; Adjusted EPS of -$0.23 Misses -$0.21 Estimate; Raises FY2026 Revenue Guidance to $270.0-$273.0 Million

  • SCHEDULE 13D/ASept. 11, 2026, 8:44 a.m. ETView on SEC.gov
  • 4Sept. 11, 2026, 8:30 a.m. ETView on SEC.gov
  • 4Sept. 11, 2026, 8:23 a.m. ETView on SEC.gov
  • 4Sept. 10, 2026, 4:21 p.m. ETView on SEC.gov
  • 4Sept. 4, 2026, 4:26 p.m. ETView on SEC.gov